Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lissoni

Showing results (201-210 of 287) with videos related to

Pageof 29
Sort By:
Journal of Biological Regulators and Homeostatic Agents|October 1, 1993
Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatoninP Lissoni, S Barni, A Ardizzoia, et al.
Tumori|June 30, 1988
Alteration of opioid peptide circadian rhythm in cancer patientsS Barni, P Lissoni, F Rovelli, et al.
Journal of Biological Regulators and Homeostatic Agents|October 19, 2000
Abrogation of surgery-induced decline in circulating dendritic cells by subcutaneous preoperative administration of IL-2 in operable cancer patientsF Brivio, P Lissoni, R Gilardi, et al.
Journal of Biological Regulators and Homeostatic Agents|March 25, 2005
Biological response modifiers of cancer-related neuroendocrine disorders: efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemiaP Lissoni, M Vaghi, S Pescia, et al.
In Vivo (Athens, Greece)|February 3, 2009
A study of surgical psychoncology in breast cancer: perioperative variation of prolactin serum levels in women with operable breast cancer in relation to their maternal psychological behaviourG Messina, P Lissoni, F Brivio, et al.
Oncology Reports|May 21, 2011
Efficacy and tolerability of cancer neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin - a progress report of 200 patients with advanced solid neoplasmsP Lissoni, A Ardizzoia, S Barni, et al.
Archivio Italiano Di Urologia, Andrologia : Organo Ufficiale [Di] Societa Italiana Di Ecografia Urologica E Nefrologica|June 1, 1997
[Immunotherapy for metastatic renal carcinoma with interleukin-2 in a subcutanous administration schedule of short duration. Subcutaneous IL-2 in renal carcinoma]P Lissoni, S Barni, A Ardizzoia, et al.
The International Journal of Biological Markers|July 1, 1989
Interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors in patients with solid tumors are not correlatedP Lissoni, V Rizzo, S Barni, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 1997
Interleukin-12 in early or advanced cancer patientsP Lissoni, F Rovelli, S Pittalis, et al.
Oncology Reports|May 21, 2011
A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patientsP Lissoni, A Ardizzoia, S Barni, et al.
Pageof 29

Showing results (201-210 of 287) with videos related to

Sort By:
Pageof 29
Journal of Biological Regulators and Homeostatic Agents|October 1, 1993
Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatoninP Lissoni, S Barni, A Ardizzoia, et al.
Tumori|June 30, 1988
Alteration of opioid peptide circadian rhythm in cancer patientsS Barni, P Lissoni, F Rovelli, et al.
Journal of Biological Regulators and Homeostatic Agents|October 19, 2000
Abrogation of surgery-induced decline in circulating dendritic cells by subcutaneous preoperative administration of IL-2 in operable cancer patientsF Brivio, P Lissoni, R Gilardi, et al.
Journal of Biological Regulators and Homeostatic Agents|March 25, 2005
Biological response modifiers of cancer-related neuroendocrine disorders: efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemiaP Lissoni, M Vaghi, S Pescia, et al.
In Vivo (Athens, Greece)|February 3, 2009
A study of surgical psychoncology in breast cancer: perioperative variation of prolactin serum levels in women with operable breast cancer in relation to their maternal psychological behaviourG Messina, P Lissoni, F Brivio, et al.
Oncology Reports|May 21, 2011
Efficacy and tolerability of cancer neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin - a progress report of 200 patients with advanced solid neoplasmsP Lissoni, A Ardizzoia, S Barni, et al.
Archivio Italiano Di Urologia, Andrologia : Organo Ufficiale [Di] Societa Italiana Di Ecografia Urologica E Nefrologica|June 1, 1997
[Immunotherapy for metastatic renal carcinoma with interleukin-2 in a subcutanous administration schedule of short duration. Subcutaneous IL-2 in renal carcinoma]P Lissoni, S Barni, A Ardizzoia, et al.
The International Journal of Biological Markers|July 1, 1989
Interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors in patients with solid tumors are not correlatedP Lissoni, V Rizzo, S Barni, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 1997
Interleukin-12 in early or advanced cancer patientsP Lissoni, F Rovelli, S Pittalis, et al.
Oncology Reports|May 21, 2011
A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patientsP Lissoni, A Ardizzoia, S Barni, et al.
Pageof 29